Ultragenyx PharmaceuticalRARE
RARE
About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Employees: 1,276
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
79% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 33
31% more capital invested
Capital invested by funds: $3.65B [Q2] → $4.77B (+$1.13B) [Q3]
23% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 90
18% more call options, than puts
Call options by funds: $28.2M | Put options by funds: $23.9M
10% more funds holding
Funds holding: 272 [Q2] → 298 (+26) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
4.67% less ownership
Funds ownership: 97.92% [Q2] → 93.25% (-4.67%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$73
67%
upside
Avg. target
$96
119%
upside
High target
$121
177%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 50% 1-year accuracy 74 / 148 met price target | 117%upside $95 | Buy Reiterated | 24 Dec 2024 |
Wells Fargo Tiago Fauth 70% 1-year accuracy 14 / 20 met price target | 101%upside $88 | Overweight Maintained | 20 Dec 2024 |
JP Morgan Anupam Rama 25% 1-year accuracy 15 / 59 met price target | 133%upside $102 | Overweight Maintained | 21 Nov 2024 |
Canaccord Genuity Whitney Ijem 25% 1-year accuracy 10 / 40 met price target | 177%upside $121 | Buy Maintained | 12 Nov 2024 |
RBC Capital Luca Issi 23% 1-year accuracy 13 / 56 met price target | 76%upside $77 | Outperform Reiterated | 6 Nov 2024 |
Financial journalist opinion
Based on 5 articles about RARE published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 15,175 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
5 days ago
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.
Neutral
GlobeNewsWire
5 days ago
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, today announced that NHS England has implemented the commissioning of Evkeeza (evinacumab) following the National Institute for Health and Care Excellence (NICE) final guidance in September. The use of Evkeeza in eligible people aged 12 years and older will be routinely commissioned by NHS England in line with the NICE TA and will be available in seven hospital trusts in England. In addition, prior approval forms are in place to enable access for children aged 5 to 11 years, via the NHS England Commissioning Medicines for Children policy.
Neutral
GlobeNewsWire
5 days ago
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025
Neutral
GlobeNewsWire
4 weeks ago
Ultragenyx to Participate in Investor Conferences in December
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
Neutral
GlobeNewsWire
1 month ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company's common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 month ago
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and higher valuation. Ultragenyx's $825M cash position and path to profitability by 2026 suggest financial stability, potentially avoiding the need for extensive dilutive financing.
Neutral
GlobeNewsWire
1 month ago
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102
Positive
Zacks Investment Research
1 month ago
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
Neutral
Seeking Alpha
1 month ago
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Chris Raymond - Piper Sandler Tazeen Ahmad - Bank of America Malcolm Kuno - JPMorgan Gena Wang - Barclays Lydia Erdman - Goldman Sachs Maury Raycroft - Jefferies Mehdi Goudarzi - Truist Securities Yaron Werber - TD Cowen Yigal Nochomovitz - Citi Thomas Yip - H.C. Wainwright Jack Allen - Baird Joe Schwartz - Leerink Partners Michael Riad - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Dae Gon Ha - Stifel Operator Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call.
Charts implemented using Lightweight Charts™